Products > Crystallization Screens > GRAS Screens > GRAS Screen™ 3 • GRAS Screen™ 4

GRAS Screen™ 3 • GRAS Screen™ 4

Applications

  • GRAS reagent crystallization screen for proteins, including monoclonal antibodies, where Salt is the primary, and Polyethylene glycol the secondary reagent, sampling pH 4-9
  • Identify GRAS based reagents that promote crystallization of biotherapeutics for bioprocess, bioformulation, and continuous flow manufacturing applications

Features

  • Developed at Hampton Research
  • Generally Recognized As Safe reagent formulation
  • Samples pH 4.0 - 9.0 without an added buffer
  • Primary crystallization reagent:
    • 24 unique salts
  • Secondary crystallization reagent:
    • GRAS Screen 3: PEG 300, 400, MME 550, & 600
    • GRAS Screen 4: PEG 1,000, MME 2,000, 3,350, & 4,000
  • Compatible with Vapor diffusion, microbatch, free interface diffusion
  • Reagents soluble between 4°C and 30°C
  • Antibody crystallization screen

Description

GRAS Screen™ 3 and GRAS Screen™ 4 were developed by Hampton Research for the crystallization of proteins, including monoclonal antibodies.

Each of the chemicals in GRAS Screen 3 and 4 have been used under one or more of the following categories. As (1) a Generally Recognized As Safe (GRAS) substance, (2) a pharmaceutical excipient, (3) a normal physiological constituent, (4) a metabolic byproduct, and/or (5) a Everything Added to Food in the United States (EAFUS) substance.

GRAS Screen 3 samples twenty four salts, encompassing pH 4-9 versus four low molecular weight Polyethylene glycols (300, 400, MME 550, & 600). GRAS Screen 3 is supplied in a 96 Deep Well block format and is compatible with robotic and multi-channel pipet liquid handling systems. GRAS Screen 3 is compatible with vapor diffusion, free interface diffusion, and microbatch crystallization methods. For research use only.

GRAS Screen 4 samples twenty four salts, encompassing pH 4-9 versus four medium molecular weight Polyethylene glycols (1,000, MME 2,000, 3,350 & 4,000). GRAS Screen 4 is supplied in a 96 Deep Well block format and is compatible with robotic and multi-channel pipet liquid handling systems. GRAS Screen 4 is compatible with vapor diffusion, free interface diffusion, and microbatch crystallization methods. For research use only.



CAT NO

HR2-453

NAME

GRAS Screen 3

DESCRIPTION

1 ml, Deep Well block format

PRICE

$144.00

CAT NO

HR2-454

NAME

GRAS Screen 4

DESCRIPTION

1 ml, Deep Well block format

PRICE

$144.00

Support Material(s)

Related Item(S)

References

1. Optimization of crystallization conditions for biological macromolecules. Alexander McPherson and Bob Cudney. Acta Crystallographica Section F Volume 70, Issue 11, pages 1445-1467, November 2014.

2. Crystallization of intact monoclonal antibodies. Harris LJ, Skaletsky E, McPherson A. Proteins. 1995 Oct;23(2):285-9.

3. Crystalline monoclonal antibodies for subcutaneous delivery. Yang MX1, Shenoy B, Disttler M, Patel R, McGrath M, Pechenov S, Margolin AL. Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):6934-9.

4. Fast and Scalable Purification of a Therapeutic Full-Length Antibody Based on Process Crystallization. Dariusch Hekmat et al, Biotechnology and Bioengineering, Vol. 110, No. 9, September, 2013.

5. Towards Protein Crystallization as a Process Step in Downstream Processing of Therapeutic Antibodies: Screening and Optimization at Microbatch Scale. Yuguo Zang et al, PLoS One. 2011; 6(9): e25282.

6. Crystallization as a tool for bioseparation. Bob Cudney, Am Biotechnol Lab. 1994 Jun;12(7):42.

7. Large-scale crystallization of proteins for purification and formulation. Hekmat D. Bioprocess Biosyst Eng. 2015 Jul;38(7):1209-31. doi: 10.1007/s00449-015-1374-y

8. Using X-Ray Crystallography to Simplify and Accelerate Biologics Drug Development. Brader ML, Baker EN, Dunn MF, Laue TM, Carpenter JF. J Pharm Sci. 2017 Feb;106(2):477-494. doi: 10.1016/j.xphs.2016.10.017.

9. Excipients and Their Role in Approved Injectable Products: Current Usage and Future Directions. Sandeep Nema and Ronald J. Brendell, PDA J Pharm Sci and Tech 2011, 65 287-332.